Pneumonia is a leading cause of death and hospitalization, costing health care systems billions of dollars and an estimated 600,000 adult deaths worldwide each year. Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae and the term describes a group of illnesses, including invasive infections, such as bacteremia/sepsis and meningitis, as well as pneumonia and upper respiratory tract infections. Although all age groups may be affected, the highest rate of pneumococcal disease occurs in young children and older adults. In addition, persons suffering from a wide range of chronic conditions (eg, diabetes, cardiovascular disease) and immune deficiencies are at increased risk.
Only 21 percent of patients with severe pneumonia caused by SARS-CoV-2 (the virus that causes COVID-19) have a documented bacterial superinfection at the time of intubation, resulting in potential overuse of antibiotics, according to new research published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.
According to a research work published in the Genome Medicine journal, travelers abroad may contract bacteria and other vectors with genes that confer antibiotic resistance, which linger in the travelers’ gut when they return home.
A preclinical study led by scientists at Sanford Burnham Prebys has established that AAV8-TNAP-D10--a gene therapy that replaces a key enzyme found in bone--may be a safe and effective single-dose treatment for hypophosphatasia (HPP).
Antibiotics used to treat common bacterial infections may potentially be used to treat human illnesses such as cancer, at least theoretically.
Researchers have discovered a new coronavirus, found in a child with pneumonia in Malaysia in 2018, that appears to have jumped from dog to human.
Researchers have now identified how SARS viruses improve the production of viral proteins in infected cells such that new copies of the virus can be produced.
Researchers at the Perelman School of Medicine at the University of Pennsylvania have produced a detailed molecular atlas of lung development, which is expected to be a fundamental reference in future studies of mammalian biology and of new treatments for diseases, such as COVID-19, that affect the lungs.
The world’s first systematic study has explained how SARS-CoV-2 and other human viruses are more adapted to infect specific types of tissues..
In the course of a new and groundbreaking study, led by Dr, Natalia Freund and the doctoral candidate Avia Waston at the Sackler Medical Faculty, the research group succeeded in isolating monoclonal antibodies, which hindered the growth of tuberculosis germs in laboratory mice.
As scientists around the globe wage war against a novel, deadly virus, one University of Colorado Boulder lab is working on new weapons to battle a different microbial threat: a rising tide of antibiotic-resistant bacteria which, if left unchecked, could kill an estimated 10 million people annually by 2050.
Researchers at the University of Maryland School of Medicine published one of the most comprehensive analyses of how genes get expressed during infection (known as a transcriptome).
In COVID-19 patients with severe lung disease, targeting the endothelial cells—that is, cells comprising the blood vessel wall, which control oxygen exchange between the bloodstream and airways—may be an innovative strategy to restore normal function of the lungs.
Molecular markers in the blood shown to be predictive of severe COVID-19 outcomes resulting from SARS-CoV-2 coronavirus infection have been identified in a study by a Chinese research team.
New insight on how bacteria in the lungs protect against invading pathogens has been published today in the open-access eLife journal.
The role of a protein in detecting the common cold virus and kickstarting an immune response to fight infection has been uncovered by a team of scientists from Nanyang Technological University, Singapore (NTU Singapore), the Agency for Science, Technology and Research (A*STAR) and the National University of Singapore.
There is an idea within the coronavirus research field that there is some kind of T cell abnormality in critically ill COVID-19 patients, but specific details have not yet been clarified. To shed light on the problem, a research collaboration based in Kumamoto University (Japan) has performed a genetic analysis of T cells from lung tissue of COVID-19 patients.
The cell membrane is the cell's outermost line of defense against SARS-CoV-2, the novel coronavirus responsible for COVID-19 disease.
Jacqueline Kimmey speaks to AZoLifeSciences about her research into bacterial pneumonia and the genes that drive its spread from the lungs into the blood.
Researchers have designed a laboratory test that can detect the microbial miscreant affecting patients hospitalized with serious infections in just six hours.
Gomila et al. recently uploaded a study to the preprint server medRxiv* (November 2020), aiming to utilize MALDI-TOF MS to analyze the sera of patients infected with SARS-CoV-2 in a range of disease severity states.